Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 20/20 | 0.81 |
| ▸ | AGTR1 | P30556 | 20/20 | 0.81 |
| ▸ | ECE1 | P42892 | 1/20 | 0.81 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1099415 | 1.00 | MME (0.81) | MMEAGTR1ECE1AGTR2 | |
| SCHEMBL1258819 | 1.00 | MME (0.81) | MMEAGTR1ECE1AGTR2 | |
| SCHEMBL1258552 | 0.94 | MME (0.72) | MMEAGTR1ECE1AGTR2 | |
| SCHEMBL1257577 | 0.94 | MME (0.79) | MMEAGTR1ECE1AGTR2 | |
| SCHEMBL1258549 | 0.94 | MME (0.72) | MMEAGTR1ECE1AGTR2 | |
| SCHEMBL1257583 | 0.94 | MME (0.79) | MMEAGTR1ECE1AGTR2 | |
| SCHEMBL1258151 | 0.94 | AGTR1 (0.78) | MMEAGTR1ECE1AGTR2 | |
| SCHEMBL1258155 | 0.94 | AGTR1 (0.78) | MMEAGTR1ECE1AGTR2 | |
| SCHEMBL1258980 | 0.94 | AGTR1 (0.71) | MMEAGTR1ECE1AGTR2 | |
| SCHEMBL1258978 | 0.94 | AGTR1 (0.71) | MMEAGTR1ECE1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2483246-B1 | PROCESS FOR PREPARING BIPHENYL IMIDAZOLE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-11-15 | — | — | EP | claimed |
| US-20150038725-A1 | PROCESS FOR PREPARING BIPHENYL IMIDAZOLE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-02-05 | — | — | US | claimed |
| EP-2350019-B1 | CRYSTALLINE FORM OF AN ALKOXYIMIDAZOL-1-YLMETHYL BIPHENYL CARBOXYLIC ACID | THERAVANCE INC (US) | 2013-07-24 | — | — | EP | claimed |
| EP-2350019-A1 | CRYSTALLINE FORM OF AN ALKOXYIMIDAZOL-1-YLMETHYL BIPHENYL CARBOXYLIC ACID | Theravance, Inc. (US) | 2011-08-03 | — | — | EP | claimed |
| US-20110077411-A1 | PROCESS FOR PREPARING BIPHENYL IMIDAZOLE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-03-31 | — | — | US | claimed |
| US-7855221-B2 | Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid | THERAVANCE, INC. (US) | 2010-12-21 | — | — | US | claimed |
| WO-2010039719-A1 | CRYSTALLINE FORM OF AN ALKOXYIMIDAZOL-1-YLMETHYL BIPHENYL CARBOXYLIC ACID | THERAVANCE, INC. (US) | 2010-04-08 | — | — | WO | claimed |
| US-20100081697-A1 | CRYSTALLINE FORM OF AN ALKOXYIMIDAZOL-1-YLMETHYL BIPHENYL CARBOXYLIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-04-01 | — | — | US | claimed |
| EP-2483246-B1 | PROCESS FOR PREPARING BIPHENYL IMIDAZOLE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2483246-B1 | PROCESS FOR PREPARING BIPHENYL IMIDAZOLE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-9273008-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-9221763-B2 | Process for preparing biphenyl imidazole compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221763-B2 | Process for preparing biphenyl imidazole compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-9150514-B2 | Dual-acting antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| WO-2010039719-A1 | CRYSTALLINE FORM OF AN ALKOXYIMIDAZOL-1-YLMETHYL BIPHENYL CARBOXYLIC ACID | THERAVANCE, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20100081697-A1 | CRYSTALLINE FORM OF AN ALKOXYIMIDAZOL-1-YLMETHYL BIPHENYL CARBOXYLIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-04-01 | — | — | US | disclosed |
| US-20100081697-A1 | CRYSTALLINE FORM OF AN ALKOXYIMIDAZOL-1-YLMETHYL BIPHENYL CARBOXYLIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-04-01 | — | — | US | disclosed |
| US-20100081697-A1 | CRYSTALLINE FORM OF AN ALKOXYIMIDAZOL-1-YLMETHYL BIPHENYL CARBOXYLIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-04-01 | — | — | US | disclosed |
| US-20090023228-A1 | Dual-acting Imidazole antihypertensive agents | THERAVANCE, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20080269305-A1 | R)-N-{2-Butyl-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl}-2-(2-hydroxycarbamoyl-3-phenyl-propionylamino)succinamic Acid; AT1 receptor antagonist and neprilysin (NEP) enzyme inhibition activity; hypertension, heart failure | THERAVANCE, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038725-A1 | PROCESS FOR PREPARING BIPHENYL IMIDAZOLE COMPOUNDS | CYP4F3, CYP1B1, BMI1 | MME 3622/4885AGTR1 729/4885ECE1 2696/4885 |
| US-20080269305-A1 | R)-N-{2-Butyl-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl}-2-(2-hydroxycarbamoyl-3-phenyl-propionylamino)succinamic Acid; AT1 receptor antagonist and neprilysin (NEP) enzyme inhibition activity; hypertension, heart failure | AGTR2, REN, AGTR1 | MME 4/4885AGTR1 3/4885ECE1 17/4885 |
| US-20110077411-A1 | PROCESS FOR PREPARING BIPHENYL IMIDAZOLE COMPOUNDS | CYP4F3, CYP1B1, BMI1 | MME 3622/4885AGTR1 729/4885ECE1 2696/4885 |
| US-20100081697-A1 | CRYSTALLINE FORM OF AN ALKOXYIMIDAZOL-1-YLMETHYL BIPHENYL CARBOXYLIC ACID | FFAR1, FFAR3, FFAR2 | MME 688/4885AGTR1 10/4885ECE1 272/4885 |
| US-20090023228-A1 | Dual-acting Imidazole antihypertensive agents | AGTR1, AGTR2, REN | MME 13/4885AGTR1 1/4885ECE1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.